Page last updated: 2024-11-07

n 0861

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N 0861: adenosine receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126615
SCHEMBL ID2828700
MeSH IDM0198470

Synonyms (14)

Synonym
n-0861 ,
n 0861
ycgmulhhh6 ,
unii-ycgmulhhh6
9h-purin-6-amine, n-bicyclo(2.2.1)hept-2-yl-9-methyl-, endo-(+-)-
141696-90-4
n(6)-endonorbornan-2-yl-9-methyladenine
SCHEMBL2828700
9h-purin-6-amine, n-(1r,2s,4s)-bicyclo(2.2.1)hept-2-yl-9-methyl-, rel-
9h-purin-6-amine, n-bicyclo(2.2.1)hept-2-yl-9-methyl-, endo-(+/-)-
DTXSID50931173
n-(bicyclo[2.2.1]heptan-2-yl)-9-methyl-9h-purin-6-amine
n-[(1s,2r,4r)-2-bicyclo[2.2.1]heptanyl]-9-methylpurin-6-amine
Z3041495701

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A2 receptors by N-0861 was evaluated by generating dose-response curves to adenosine-induced bradycardia (A1 effect), and vasodilation in the in situ constant-flow perfused rat hindquarter vasculature (A2 effect)."( N-0861 selectively antagonizes adenosine A1 receptors in vivo.
Barrett, RJ; Droppleman, DA; Wright, KF, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (90.00)18.2507
2000's2 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.07 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]